Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
We intend to compare the efficacy and safety of immunotherapy plus stereotactic body
radiotherapy at oligometastatic lesions and immunotherapy alone among patients with
oligometastatic nasopharyngeal carcinoma whose primary lesion has been well controlled after
radical local-regional treatment through this multicenter randomized phase 3 trial.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Affiliated Cancer Hospital & Institute of Guangzhou Medical University Guangdong Provincial People's Hospital Zhongshan People's Hospital, Guangdong, China